[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Universitas Diponegoro\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":271},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,48,78,107,129,156,183,207,227,249],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100597991","phase-1-effetivity-of-dutasteride-and-aloe-vera-extract-combination-on-angiogenesis-and-obstruction-on-benign-prostatic-hyperplasia-100597991",false,"NCT07065682","Effetivity of Dutasteride and Aloe Vera Extract Combination on Angiogenesis and Obstruction on Benign Prostatic Hyperplasia","ALOE-DUTA-BPH","Inclusion Criteria:\n\n* Diagnosed with BPH clinically or radiologically (prostate volume \\> 30 gram, Qmax \\\u003C15 mL\u002Fs)\n* Willing to participate to the study\n\nExclusion Criteria:\n\n* Clinically or radiologically suspected of having prostatic cancer\n* Previous prostatic surgery\n* Patients with urinary retention\n* Patients with BPH complications: urinary tract infections, urolithiasis, or hydroneprhosis\n* Previously consumed alpha blocker or 5ARI in the last 6 months\n* Have consumed aloe vera extract routinely","MALE","50 Years",{"count":19,"type":20},84,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","This study is a double blinded RCT with pre-post test design on the effect of combination of dutasteride and aloe vera, compared to dutasteride only, on uroflowmetry results, prostate volume, and VEGF serum level among patients with benign prostate hyperplasia. The treatment was given for 12 weeks",[26],"BPH (Benign Prostatic Hyperplasia)",[28,29,30,31,32,33,34],"Aloe Vera","Benign prostate hyperplasia","VEGF","Prostate","dutasteride","uroflowmetry","prostatic hyperplasia","RECRUITING","2025-07-03",{"date":38,"type":39},"2025-07-15","ACTUAL",{"date":41,"type":39},"2023-07-01",{"date":43,"type":20},"2027-12-01",{"name":45,"class":46},"Universitas Diponegoro","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":55,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":21,"phases":60,"briefSummary":62,"conditions":63,"keywords":65,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":47},"100597466","the-effect-of-low-level-tragus-stimulation-on-echocardiographic-parameters-in-patients-with-st-segment-elevation-myocardial-infarction---a-single-centre-randomized-control-trial-100597466","NCT07058857","The Effect of Low-Level Tragus Stimulation on Echocardiographic Parameters in Patients With ST-Segment Elevation Myocardial Infarction - A Single-Centre Randomized Control Trial","ELITE-STEMI","Inclusion Criteria:\n\n* Onset STEMI less than 12 hours\n* Participant agreed to be included in this study\n* Killip class I - II on presentation\n* SBP \\>90 mmHg and\u002For MAP \\>65 mmHg\n* Sinus rhtyhm\n\nExclusion Criteria:\n\n* History of myocardial infarction, stroke, heart failure with reduce ejection fraction, chronic total occlussion on prior coronary angiography, chronic kidney disease (eGFR \\\u003C 30) or on hemodyalisis, malignancy, hematology disease, autoimmune, or other chronic diseases\n* On permanent pacemaker\n* Acute infection\n* Pregnant woman","ALL","18 Years","75 Years",{"count":59,"type":20},100,[61],"NA","The goal of this clinical trial is to learn the effect of low level tragus stimulation (LLTS) on echocardiographic parameter in patient with ST-segment Elevation Myocardial Infarction (STEMI) who undergo primart percutaneous coronary intervention (PPCI). It will also learn about the safety of LLTS in such setting. The main questions, it aims to answer are compared with sham control:\n\nDoes LLTS could alter left ventricular ejection fraction in patients with STEMI? Does LLTS could alter wall motion score index in patients with STEMI? Does LLTS could alter diastolic dysfunction in patients with STEMI?\n\nResearchers will compare LLTS to sham LLTS control to see if LLTS have benefit in participants with STEMI participants will divided into two group i.e. treatment group vs control (sham\u002Fplacebo) group..\n\nBoth groups undergo transthoracal echocardiographi examination before and after PPCI..",[64],"ST Elevation Myocardial Infarction",[66,67,68,69],"ST-segment elevation myocardial infarction","Low level tragus stimulation","Left ventricular ejection fraction","Wall motion score index","2025-06-30",{"date":72,"type":39},"2025-07-10",{"date":74,"type":39},"2025-01-01",{"date":76,"type":20},"2025-09-30",{"name":45,"class":46},{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":55,"minAge":85,"maxAge":86,"enrollmentInfo":87,"targetDuration":4,"studyType":21,"phases":89,"briefSummary":90,"conditions":91,"keywords":4,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":47},"100593804","phase-1-clinical-outcomes-of-early-kasai-surgery-with-umbilical-cord-mscs-in-biliary-atresia-100593804","NCT07011199","Clinical Outcomes of Early Kasai Surgery With Umbilical Cord MSCs in Biliary Atresia","Evaluation of Clinical Outcomes in Biliary Atresia Patients Undergoing Kasai Surgery Before 90 Days of Age With Umbilical Cord-Derived Mesenchymal Stem Cell Therapy","Inclusion Criteria:\n\n* Infants diagnosed with biliary atresia confirmed by intraoperative findings.\n* Underwent Kasai portoenterostomy at an age less than 90 days.\n* Parents or legal guardians have provided informed consent to participate in the study and follow all study procedures.\n\nExclusion Criteria:\n\n* Infants with severe malnutrition.\n* Infants with major congenital anomalies other than biliary atresia.\n* Infants with positive tumor markers.","0 Days","90 Days",{"count":88,"type":20},14,[23],"The goal of this clinical trial with historical control is to evaluate whether umbilical cord-derived mesenchymal stem cell (UC-MSC) therapy can improve clinical outcomes in infants with biliary atresia undergoing Kasai surgery before 90 days of age.\n\nThe main questions it aims to answer are:\n\nDoes UC-MSC therapy improve liver function parameters (bilirubin, albumin, liver enzymes, coagulation profile)? Does UC-MSC therapy reduce complications such as anemia, ascites, jaundice, and improve PELD scores? Does UC-MSC therapy improve overall survival compared to standard Kasai surgery alone? Researchers will compare the group receiving UC-MSC in 2025-2027 with a historical control group of patients who previously underwent Kasai surgery without UC-MSC therapy.\n\nParticipants will:\n\nUndergo preoperative evaluation, including laboratory and imaging tests. Receive Kasai surgery combined with intraoperative trans-portal vein injection of 20 million UC-MSCs.\n\nBe monitored postoperatively through serial laboratory tests, imaging (Fibroscan), and clinical assessments at scheduled intervals.\n\nBe followed up for potential serious adverse events and survival outcomes.",[92,93,94,95,96,97],"Biliary Atresia","Kasai Portoenterostomy","Mesenchymal Stem Cell Transplantation","Liver Function Disorders","Liver Fibrosis","Survival Rate","NOT_YET_RECRUITING","2025-05-30",{"date":101,"type":39},"2025-06-08",{"date":103,"type":20},"2025-06-17",{"date":105,"type":20},"2026-04-17",{"name":45,"class":46},{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":111,"acronym":112,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":55,"minAge":56,"maxAge":114,"enrollmentInfo":115,"targetDuration":4,"studyType":117,"phases":4,"briefSummary":118,"conditions":119,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":47},"100575994","validation-and-assessment-of-novel-morphology-voltage-p-wave-score-for-diagnosing-left-ventricular-diastolic-dysfunction-in-patients-with-hypertension-100575994","NCT06779513","Validation and Assessment of Novel Morphology-Voltage-P-wave Score for Diagnosing Left Ventricular Diastolic Dysfunction in Patients With Hypertension","VANESSA","Inclusion Criteria:\n\n* Essential hypertension\n\nExclusion Criteria:\n\n* Secondary or resistant hypertension\n* LVEF\\\u003C55%\n* Congenital heart disease\n* Infiltrative cardiomyopathy\n* Coronary artery disease\n* Chronic kidney disease\n* Valvular heart disease\n* Bundle branch block\n* Arrhythmia","70 Years",{"count":116,"type":20},50,"OBSERVATIONAL","This study aimed to assess and validate the diagnostic utility of a novel Morphology-Voltage-P-wave Score (MVP Score) in identifying left ventricular diastolic dysfunction among patients with hypertension.\n\nResearchers will collect information of patient with hypertension and underwent transthoracal echocardiography assessment. The data consist of demographic data, clinical presentation, laboratory, and echocardiography result were collected by two investigators. Then, the data was analyzed by using IBM SPSS Statistics v26.",[120],"Hypertension","2025-01-11",{"date":123,"type":39},"2025-01-16",{"date":125,"type":39},"2024-01-01",{"date":127,"type":20},"2025-03-15",{"name":45,"class":46},{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":4,"eligibilityCriteria":135,"healthyVolunteers":11,"sex":55,"minAge":136,"maxAge":137,"enrollmentInfo":138,"targetDuration":4,"studyType":21,"phases":139,"briefSummary":140,"conditions":141,"keywords":143,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":47},"100561117","synbiotics-impact-on-insulin-and-tnf--in-mafld-a-gut-microbiota-profile-analysis-100561117","NCT06585982","Synbiotics Impact on Insulin and TNF-α in MAFLD: a Gut Microbiota Profile Analysis","Gut Microbiota Profile Analysis and Randomized Controlled Trials (RCT) Study of the Effect of Synbiotics on Insulin and TNF-α in Metabolic Dysfunction -Associated Fatty Liver Disease (MAFLD)","Inclusion Criteria:\n\n1. Adult patients aged 25-55 years\n2. Patients are willing to become research respondents after filling out informed consent\n3. Patients can and are willing to consume supplements orally within a predetermined time\n4. Patients are willing to record compliance with taking supplements in a diary that has been provided\n5. Patients diagnosed with MAFLD by FibroScan interpreted by a specialist in gastroenterology-hepatology with a CAP score ≥263 dB\u002Fm\n\nExclusion Criteria:\n\n1. Patients with hepatitis (hepatitis B, hepatitis C, and autoimmune hepatitis) and alcoholic liver disease, cirrhosis of the liver\n2. Patients who are pregnant, or breastfeeding or in a programme to become pregnant during participation in this study.\n3. Patients with a history of alcohol consumption \\>40 g\u002Fday.\n4. Patients with a history of decompensated disease including ascites, encephalopathy, variceal haemorrhage\n5. Patients with Hepatocellular Carcinoma (HCC)\n6. Patients with a history of bowel resection or bariatric surgery Patients with chronic inflammatory bowel disease (IBD)\n7. Patients with a history of antibiotic use or probiotic\u002Fprebiotic\u002Fsynbiotic consumption in the past 1 month\n8. Use of Vitamin E and omega-3 fatty acids\n9. Patients who were not hospitalised in the last month and therefore did not have any food restrictions related to their illness.","25 Years","55 Years",{"count":116,"type":20},[61],"Primary Objective: To analyze the effect of synbiotic supplementation on metabolic profile, insulin and TNF-α and gut microbiota changes in patients with Metabolic dysfunction-Associated Fatty Liver Disease (MAFLD).\n\nResearch question: Are there any changes in metabolic profile, Insulin and TNF-α and gut microbiota changes in MAFLD patients after synbiotic supplementation\n\nParticipants will:\n\n* Treatment group given supplementation and the control group will be given placebo at a dose of 2x1 tablet for 12 weeks.\n* Patients will visit the hospital every 28 days for up to 4 months for control and follow-up supplementation.\n* patients will be given a supplement consumption compliance logbook and a food record logbook used to record food consumption filled in by the patient.",[142],"Fatty Liver Disease",[144,145,146,147],"Metabolic dysfunction-associated fatty liver disease","Gut Microbiota","Metabolic profile","Synbiotic","2024-11-07",{"date":150,"type":39},"2024-11-12",{"date":152,"type":39},"2024-03-04",{"date":154,"type":20},"2025-03-07",{"name":45,"class":46},{"id":157,"slug":158,"hasResults":11,"nctId":159,"briefTitle":160,"officialTitle":161,"acronym":162,"eligibilityCriteria":163,"healthyVolunteers":11,"sex":55,"minAge":56,"maxAge":4,"enrollmentInfo":164,"targetDuration":4,"studyType":21,"phases":166,"briefSummary":168,"conditions":169,"keywords":171,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":177,"completionDateStruct":179,"leadSponsor":181,"locationsCount":182},"100552593","phase-4-combination-oral-acetazolamide-and-intravenous-furosemide-on-acute-decompensated-heart-failure-outcomes-100552593","NCT06475105","Combination Oral Acetazolamide and Intravenous Furosemide on Acute Decompensated Heart Failure Outcomes","Effects of Combination Oral Acetazolamide and Intravenous Furosemide on Acute Decompensated Heart Failure","COAF-HF","Inclusion Criteria:\n\n* Agree to be included in the research by signing informed consent\n* Patients with a clinical diagnosis of acute decompensated heart failure with at least one clinical sign of volume overload with a congestion score ≥2 (ADVOR Score) (e.g. edema (score 2 or more), ascites confirmed by physical examination or ultrasonography or pleural effusion confirmed by chest x-ray or echocardiography).\n* Patients on routine oral loop diuretic therapy with a dose of ≥40 mg furosemide for ≥1 month\n* Plasma NT-proBNP levels that increase ≥300 pg\u002FmL or the applicable cut-off according to the age range at the time of examination in the ER.\n\nExclusion Criteria:\n\n* Subjects with acute coronary syndrome\n* History of congenital heart disease requiring surgical correction.\n* Subjects in cardiogenic shock.\n* Estimated glomerular filtration rate \\\u003C20 mL\u002Fmin\u002F1.73m² at the time of examination.\n* Use of renal replacement therapy or ultrafiltration at any time before the study was included.\n* Treatment with acetazolamide within 1 month before randomization.\n* Exposure to nephrotoxic agents (i.e. contrast dye) is anticipated within the next 3 days\n* Subjects who are pregnant or breastfeeding.\n* Subjects with urinary incontinence who are unwilling to use a bladder catheter.",{"count":165,"type":20},66,[167],"PHASE4","Based on ADVOR trial, the potential of adding acetazolamide in increasing the success of decongestion, the amount of natriuresis and diuresis. However, the use of intravenous acetazolamide may not be possible in Indonesia, where the intravenous formulation is not available. This clinical research study is being conducted in single hospitals in Indonesia. We aim to learn if Oral Acetazolamide in addition to Furosemide intravenous works to treat congestion in Acute Decompensated Heart Failure, besides evaluating the total urinary output, change of NT pro BNP level, and safety profile of oral Acetazolamide.\n\nThe hypothesis of this study is oral acetazolamide works well to achieve successful decongestion.",[170],"Acute Decompensated Heart Failure",[172,170,173],"Oral Acetazolamide","Congestion","2024-10-20",{"date":176,"type":39},"2024-10-22",{"date":178,"type":39},"2024-04-20",{"date":180,"type":20},"2024-12-31",{"name":45,"class":46},2,{"id":184,"slug":185,"hasResults":11,"nctId":186,"briefTitle":187,"officialTitle":187,"acronym":188,"eligibilityCriteria":189,"healthyVolunteers":11,"sex":55,"minAge":56,"maxAge":114,"enrollmentInfo":190,"targetDuration":192,"studyType":117,"phases":4,"briefSummary":193,"conditions":194,"keywords":196,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":201,"startDateStruct":203,"completionDateStruct":204,"leadSponsor":206,"locationsCount":47},"100561151","the-prognostic-value-of-anion-gap-in-predicting-major-adverse-cardiovascular-events-among-patients-with-st-segment-elevation-myocardial-infarction-100561151","NCT06586424","The Prognostic Value of Anion Gap in Predicting Major Adverse Cardiovascular Events Among Patients With ST-Segment Elevation Myocardial Infarction","ANGIO-STEMI","Inclusion Criteria:\n\n* Adults with 18 - 70 years old with diagnosis of STEMI who underwent PPCI\n\nExclusion Criteria:\n\n* History of heart failure due to any causes\n* Cardiogenic shock before PPCI\n* Any infection at the time of presentation\n* Pregnant woman\n* Other causes of high anion gap levels such as chronic kidney disease, metabolic acidosis, etc",{"count":191,"type":20},80,"7 Days","This study aims to evaluate the prognostic value of the anion gap in predicting major adverse cardiovascular events among patients with ST-segment elevation myocardial infarction. Researchers will collect information based on hospital registry as secondary data of in patient who had diagnosed as ST-segment elevation myocardial infarction and underwent primary percutaneous coronary intervention. The data consist of demographic data, clinical presentation, laboratory, and angiography result were collected from hospital registry by reviewing medical record. Then, the data was analyzed by using IBM SPSS Statistics v26.",[195],"ST-segment Elevation Myocardial Infarction (STEMI)",[197,198,199],"anion gap","major adverse cardiovascular events","st-segment elevation myocardial infarction","2024-09-03",{"date":202,"type":39},"2024-09-19",{"date":125,"type":39},{"date":205,"type":20},"2024-10-05",{"name":45,"class":46},{"id":208,"slug":209,"hasResults":11,"nctId":210,"briefTitle":211,"officialTitle":211,"acronym":212,"eligibilityCriteria":213,"healthyVolunteers":11,"sex":55,"minAge":56,"maxAge":114,"enrollmentInfo":214,"targetDuration":192,"studyType":117,"phases":4,"briefSummary":216,"conditions":217,"keywords":218,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":222,"startDateStruct":223,"completionDateStruct":224,"leadSponsor":226,"locationsCount":47},"100561119","the-association-between-visual-echocardiographic-scoring-system-and-clinical-outcomes-in-patient-with-acute-decompensated-heart-failure-100561119","NCT06586008","The Association Between Visual Echocardiographic Scoring System and Clinical Outcomes in Patient With Acute Decompensated Heart Failure","VISCO-HF","Inclusion Criteria:\n\n* Patient with history of heart failure with reduced ejection fraction (LVEF \\\u003C40%)\n* Age between 18 - 70 years old\n\nExclusion Criteria:\n\n* Patient with pulmonary hypertension\n* Patient with acute de novo heart failure (e.g. due to acute coronary syndrome)\n* Significant valvular heart disease (more than moderate regurgitation or more than mild stenosis)\n* Prior valve replacement\u002Frepair\n* Patient with congenital heart disease\n* Patient with pericardial disease\n* Patient with poor echocardiographic images",{"count":215,"type":20},150,"This study aims to evaluate the association between visual echocardiographic scoring system (visual mitral and tricuspid = VMT score) with clinical outcome among patients with acute decompensated heart failure. Researchers will collect information based on hospital registry as secondary data of in patient who had diagnosed as acute decompensated heart failure. The data consist of demographic data, clinical presentation, laboratory, and echocardiographic result were collected from hospital registry by reviewing medical record and echocardiographic machine database. Then, the data was analyzed by using IBM SPSS Statistics v26.",[170],[219,220,221],"visual echocardiographic system","acute decompensated heart failure","mortality",{"date":202,"type":39},{"date":125,"type":39},{"date":225,"type":20},"2024-11-10",{"name":45,"class":46},{"id":228,"slug":229,"hasResults":11,"nctId":230,"briefTitle":231,"officialTitle":231,"acronym":232,"eligibilityCriteria":233,"healthyVolunteers":11,"sex":55,"minAge":56,"maxAge":114,"enrollmentInfo":234,"targetDuration":192,"studyType":117,"phases":4,"briefSummary":236,"conditions":237,"keywords":239,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":241,"lastUpdatePostDateStruct":242,"startDateStruct":244,"completionDateStruct":246,"leadSponsor":248,"locationsCount":47},"100560935","the-prognostic-value-of-anion-gap-in-predicting-mortality-among-patients-with-acute-pulmonary-embolism-100560935","NCT06583616","The Prognostic Value of Anion Gap in Predicting Mortality Among Patients With Acute Pulmonary Embolism","PRAGUE-PE","Inclusion Criteria:\n\n* age: 18 - 70 years old\n* patient with acute pulmonary embolism\n\nExclusion Criteria -- patient with history of:\n\n* heart failure\n* valvular heart disease\n* chronic obstructive pulmonary disease\n* congenital heart disease\n* sepsis\n* chronic kidney disease",{"count":235,"type":20},20,"This study aims to evaluate the prognostic value of the anion gap in predicting mortality among patients with acute pulmonary embolism.\n\nResearchers will collect information based on hospital registry as secondary data of in patient who had diagnosed as acute pulmonary embolism by using computed tomography scan (CT scan). The data consist of demographic data, clinical presentation, laboratory, and CT scan were collected from hospital registry by reviewing medical record. Then, the data was analyzed by using IBM SPSS Statistics v26.",[238],"Acute Pulmonary Embolism (PE)",[197,240,221],"acute pulmonary embolism","2024-09-02",{"date":243,"type":39},"2024-09-04",{"date":245,"type":39},"2023-01-01",{"date":247,"type":20},"2024-09-30",{"name":45,"class":46},{"id":250,"slug":251,"hasResults":11,"nctId":252,"briefTitle":253,"officialTitle":254,"acronym":255,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":55,"minAge":56,"maxAge":114,"enrollmentInfo":256,"targetDuration":4,"studyType":21,"phases":257,"briefSummary":258,"conditions":259,"keywords":260,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":265,"lastUpdatePostDateStruct":266,"startDateStruct":268,"completionDateStruct":269,"leadSponsor":270,"locationsCount":47},"100557397","the-efficacy-and-safety-of-low-level-tragus-stimulation-on-heart-rate-variability-neutrophil-lymphocyte-ratio-and-major-adverse-cardiovascular-events-in-patients-with-st-segment-elevation-myocardial-infarction-tesla-stemi-100557397","NCT06537583","The Efficacy and Safety of Low-Level Tragus Stimulation on Heart Rate Variability, Neutrophil-Lymphocyte Ratio, and Major Adverse Cardiovascular Events in Patients With ST-Segment Elevation Myocardial Infarction (TESLA-STEMI)","The Efficacy and Safety of Low-Level Tragus Stimulation on Heart Rate Variability, Neutrophil-Lymphocyte Ratio, and Major Adverse Cardiovascular Events in Patients With ST-Segment Elevation Myocardial Infarction","TESLA-STEMI",{"count":59,"type":20},[61],"The goal of this clinical trial is to learn the effect of low level tragus stimulation (LLTS) on heart rate variability (HRV), neutrophil-lymphocyte ratio, and major adverse cardiovascular events in patient with ST-segment Elevation Myocardial Infarction (STEMI). It will also learn about the safety of LLTS in such setting. The main questions, it aims to answer are compared with sham control:\n\n1. Does LLTS could alter low frequency\u002Fhigh frequency ratio in patients with STEMI?\n2. Does LLTS could alter neutrophil-lymphocyte ratio in patients with STEMI?\n3. Does LLTS could decrease mortality in patients with STEMI?\n4. Does LLTS could decrease reinfarction event in patients with STEMI?\n5. Does LLTS could decrease stroke event in patients with STEMI?\n6. Does LLTS could decrease lethal arrhythmia event in patients with STEMI?\n7. Does LLTS could decrease acute lung oedema event in patients with STEMI?\n8. Does LLTS could decrease cardiogenic shock event in patients with STEMI?\n\nResearchers will compare LLTS to sham LLTS control to see if LLTS have benefit in participants with STEMI participants will divided into two group i.e. treatment group vs control (sham\u002Fplacebo) group, then both of them:\n\n1. Undergo laboratory examination before Primary Percutaneous Coronary Intervention (PPCI)\n2. Undergo HRV measurement using WeCardio device before Primary Percutaneous Coronary Intervention (PPCI)\n3. Undergo LLTS (treatment group will have stimulation) for 60 minutes, however, sham control will not have stimulation, before PPCI\n4. Undergo PPCI\n5. Undergo laboratory examination after Primary Percutaneous Coronary Intervention (PPCI)\n6. Undergo HRV measurement using WeCardio device after Primary Percutaneous Coronary Intervention (PPCI)",[64],[261,67,262,263,264],"ST segment elevation myocardial infarction","Heart rate variability","Neutrophil-lymphocyte ratio","Major adverse cardiovascular events","2024-07-31",{"date":267,"type":39},"2024-08-05",{"date":125,"type":39},{"date":247,"type":20},{"name":45,"class":46},""]